Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

CVS Health CVS shares have rallied nearly 38% so far this month, driven by the company’s stronger-than-expected first-quarter ...

India's commercial vehicle (CV) sales aim to cross 1 million units in FY26 after two slow years. Improved freight rates, ...

CVS Health (CVS) stock in focus as Glenview Capital trims a third of its stake after the company's Q1 2025 earnings beat.

CVS Health has raised its full-year profit forecast, driven by robust performance across its sectors and strategic ... CVS anticipates improved financial health amid growing healthcare demands from ...

Investing.com -- CVS Caremark announced a partnership with Novo Nordisk (NYSE:NVO) to expand access to Wegovy, a GLP-1 drug for obesity, at a more affordable price. Starting July 1, 2025, Wegovy will ...

The updated guidance is detailed in the following slide: CVS Health’s first quarter results demonstrate the company’s ability to execute on its strategic priorities while delivering strong financial ...

CVS Health President and CEO. The company’s Health Care Benefits segment saw adjusted operating income surge to $1.99 billion from $732 million a year ago, driven by favorable prior-year development ...

Following the earnings release, CVS Health’s stock surged 8.8% in premarket trading, reflecting investor confidence in the company’s strategic direction and financial performance. According to ...

CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be ...